A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Oct 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CDNA SEC filings page.
CareDx, Inc. (CDNA) reported $497.4M in revenue over the twelve months to Sep 30, 2026, up 38.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Profitability reversed in FY2025 despite higher revenue, while positive operating cash flow and shareholder payouts reshaped the balance sheet.
FY2024 profit was not fully matched by cash: operating cash flow equaled72.4% of net income, indicating some earnings did not convert immediately. In FY2025, operating cash flow reached$42.0M alongside a net loss of$21.4M ; together with rising inventory and falling receivables, that points to accounting and working-capital timing affecting the gap.
Revenue grew
Short-term balance-sheet capacity narrowed: the current ratio fell from 3.9x to 2.9x as current assets contracted while current liabilities stayed broadly level. FY2025 financing cash flow was
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of CareDx, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. CareDx, Inc. scores 17/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. CareDx, Inc. scores 77/100 on it among other operating companies.
CareDx, Inc. carried $0.36 of total liabilities for every $1 of shareholders' equity at the end of fiscal year 2025. With no long-term debt figure for fiscal year 2025, CareDx, Inc. is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 65/100 among other operating companies measured the same way.
CareDx, Inc. held $2.86 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 2.86. Liquidity ranks operating companies on that ratio, and CareDx, Inc. scores 77/100 among other operating companies.
Not available for CareDx, Inc., so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. CareDx, Inc. scores 18/100 on it among other operating companies.
CareDx, Inc. scores 20.41, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $3.9B against total liabilities of $110.1M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
CareDx, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.
CareDx, Inc. reported a net loss of $21.4M while generating $42.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
CareDx, Inc. generated $139.4M in revenue in Q3 2026. This represents an increase of 39.3% from the same quarter a year earlier. Against the prior quarter it is up 5.6%.
CareDx, Inc.'s EBITDA was $15.3M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 329.3% from the same quarter a year earlier. Against the prior quarter it is down 86.8%.
CareDx, Inc. reported $19.3M in net income in Q3 2026. This represents an increase of 1051.8% from the same quarter a year earlier. Against the prior quarter it is down 82.6%.
CareDx, Inc. earned $0.35 per diluted share (EPS) in Q3 2026. This represents an increase of 1066.7% from the same quarter a year earlier. Against the prior quarter it is down 83.1%.
Cash & Balance Sheet
CareDx, Inc. generated $11.1M in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 69.2% from the same quarter a year earlier. Against the prior quarter it is down 61.4%.
CareDx, Inc. held $250.5M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
CareDx, Inc.'s operating margin was 5.8% in Q3 2026, reflecting core business profitability. This is up 6.1 percentage points from the same quarter a year earlier. Against the prior quarter it is down 80.0 percentage points.
CareDx, Inc.'s net profit margin was 13.8% in Q3 2026, showing the share of revenue converted to profit. This is up 12.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 70.0 percentage points.
CareDx, Inc.'s quarterly ROE was 4.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 3.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 21.9 percentage points.
Not reported for Q3 2026.
Capital Allocation
CareDx, Inc. invested $21.3M in research and development in Q3 2026. This represents an increase of 27.2% from the same quarter a year earlier. Against the prior quarter it is down 4.7%.
CareDx, Inc. repurchased no shares in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
CareDx, Inc. invested $1.6M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 23.8% from the same quarter a year earlier. Against the prior quarter it is down 13.1%.
CDNA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $139.4M+39.3% | $131.9M+52.2% | $117.7M+39.0% | $108.4M+25.2% | $100.1M+20.7% | $86.7M-6.1% | $84.7M+17.5% | $86.6M+32.0% |
| R&D Expenses | $21.3M+27.2% | $22.4M+33.0% | $21.4M+15.6% | $19.3M+16.2% | $16.8M-4.1% | $16.8M-14.5% | $18.5M-1.0% | $16.6M-11.7% |
| SG&A Expenses | $69.6M+31.7% | $74.3M+43.1% | $60.9M+33.0% | $59.6M+11.0% | $52.9M+2.6% | $52.0M+0.1% | $45.8M-8.4% | $53.7M+11.3% |
| Operating Income | $8.1Mn/m | $113.2Mn/m | $1.2Mn/m | -$6.0M-107.2% | -$246Kn/m | -$11.1Mn/m | -$13.4Mn/m | $84.4Mn/m |
| EBITDA | $15.3M+329.3% | $116.0Mn/m | $5.1Mn/m | -$2.2M-102.5% | $3.6Mn/m | -$7.4Mn/m | -$9.8Mn/m | $87.7Mn/m |
| Income Tax | -$8.6Mn/m | $3.9Mn/m | -$32K-155.2% | $345K+101.8% | -$15K-107.5% | -$117K-631.8% | $58Kn/m | $171K+3.6% |
| Net Income | $19.3M+1051.8% | $110.6Mn/m | $2.8Mn/m | -$4.1M-104.7% | $1.7Mn/m | -$8.6Mn/m | -$10.4Mn/m | $87.7Mn/m |
| EPS (Basic) | $0.37+1133.3% | $2.15n/m | $0.05n/m | -$0.08-104.8% | $0.03n/m | -$0.16n/m | -$0.19n/m | $1.67n/m |
| EPS (Diluted) | $0.35+1066.7% | $2.07n/m | $0.05n/m | -$0.08-105.0% | $0.03n/m | -$0.16n/m | -$0.19n/m | $1.60n/m |
| Diluted Shares (Avg) | 55M+2.3% | 53M-1.6% | 53M-3.9% | N/A | 54M+1.6% | 54M+4.0% | 55M+6.9% | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
CDNA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $641.5M+48.4% | $533.0M+20.0% | $411.1M-16.0% | $413.2M-15.8% | $432.3M-9.4% | $444.3M-4.8% | $489.6M+8.2% | $491.1M+5.2% |
| Current Assets | $321.3M+7.0% | $429.2M+39.7% | $269.4M-23.1% | $257.1M-26.9% | $300.3M-10.1% | $307.3M-4.2% | $350.2M+15.6% | $351.8M+12.2% |
| Cash & Equivalents | $250.5M+173.9% | $373.6M+447.8% | $77.9M-12.2% | $65.4M-43.0% | $91.4M-4.2% | $68.2M-28.8% | $88.7M-4.9% | $114.7M+39.5% |
| Short-Term Investments | $0-100.0% | $0-100.0% | $109.3M-23.2% | $111.8M-23.4% | $102.8M-29.3% | $118.0M-11.3% | $142.2M+15.9% | $146.0M-4.7% |
| Inventory | $9.1M-67.7% | $7.0M-75.0% | $26.4M+15.2% | $26.7M+36.9% | $28.3M+47.1% | $27.9M+45.1% | $22.9M+13.9% | $19.5M+0.2% |
| Accounts Receivable | $47.7M-0.2% | $34.4M-49.0% | $44.6M-37.6% | $42.6M-34.0% | $47.8M-28.2% | $67.4M+1.8% | $71.5M+18.8% | $64.6M+26.5% |
| Long-Term Investments | $0n/m | $0n/m | $10.9Mn/m | $24.2Mn/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $121.7M+201.7% | $36.0M-10.8% | $40.3M0.0% | $40.3M0.0% | $40.3M0.0% | $40.3M0.0% | $40.3M0.0% | $40.3M0.0% |
| Total Liabilities | $174.0M+43.6% | $107.4M-8.1% | $97.5M-11.6% | $110.1M-2.2% | $121.2M-40.5% | $116.9M-42.2% | $110.3M-43.8% | $112.6M-45.2% |
| Current Liabilities | $139.0M+40.3% | $93.7M+0.6% | $79.2M-7.2% | $89.8M+0.5% | $99.0M+21.6% | $93.2M+19.0% | $85.3M+21.5% | $89.4M+14.5% |
| Non-Current Liabilities | $35.0M+58.3% | $13.7M-42.2% | $18.4M-26.5% | $20.3M-12.8% | $22.1M-81.9% | $23.7M-80.8% | $25.0M-80.2% | $23.2M-81.8% |
| Total Equity | $467.5M+50.2% | $425.6M+30.0% | $313.5M-17.3% | $303.1M-19.9% | $311.1M+13.9% | $327.4M+23.7% | $379.3M+48.1% | $378.4M+44.8% |
| Retained Earnings | -$486.2Mn/m | -$505.4Mn/m | -$732.5Mn/m | -$618.9Mn/m | -$719.0Mn/m | -$695.2Mn/m | -$636.6Mn/m | -$626.2Mn/m |
Not reported in any period shown, so not listed: Long-Term Debt.
CDNA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $12.7M-66.0% | $30.6M+209.3% | $4.3Mn/m | $21.4M-2.4% | $37.4M+198.3% | $9.9M-47.8% | -$26.6Mn/m | $21.9Mn/m |
| Depreciation & Amortization | $7.2M+88.9% | $2.8M-24.5% | $3.9M+8.3% | $3.9M+15.5% | $3.8M+9.9% | $3.7M+5.1% | $3.6M-5.8% | $3.4M-7.4% |
| Stock-Based Compensation | $9.7M+14.7% | $10.7M+13.1% | $9.8M+9.8% | N/A | $8.4M-50.3% | $9.4M-42.5% | $8.9M-46.1% | N/A |
| Capital Expenditures | $1.6M+23.8% | $1.9M+84.5% | $3.8M+134.3% | N/A | $1.3M | $1.0M | $1.6M | N/A |
| Free Cash Flow | $11.1M-69.2% | $28.7M+223.4% | $514Kn/m | N/A | $36.1M | $8.9M | -$28.2M | N/A |
| Investing Cash Flow | -$147.9M-1297.5% | $280.6M+1099.2% | $11.1M+734.6% | -$34.9Mn/m | $12.3Mn/m | $23.4Mn/m | $1.3M-95.2% | -$2.1M-105.1% |
| Financing Cash Flow | $12.9Mn/m | -$15.5Mn/m | -$2.9Mn/m | -$12.5Mn/m | -$26.5M-1962.0% | -$53.8Mn/m | -$643Kn/m | -$903Kn/m |
| Share Buybacks | $0-100.0% | N/A | N/A | $12.2Mn/m | $25.6Mn/m | $50.0Mn/m | $0-100.0% | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid.
CDNA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 5.8%+6.1pp | 85.8%+98.6pp | 1.0%+16.8pp | -5.6%-103.0pp | -0.3%+16.3pp | -12.8%-4.9pp | -15.8%+15.5pp | 97.5% |
| Net Margin | 13.8%+12.2pp | 83.9%+93.7pp | 2.4%+14.6pp | -3.8% | 1.7%+14.5pp | -9.9%-4.9pp | -12.2%+15.4pp | 101.3% |
| Return on Equity | 4.1%+3.6pp | 26.0%+28.6pp | 0.9%+3.6pp | -1.4%-24.5pp | 0.5%+4.4pp | -2.6%-0.9pp | -2.7%+5.0pp | 23.2%+68.4pp |
| Return on Assets | 3.0%+2.6pp | 20.8%+22.7pp | 0.7%+2.8pp | -1.0%-18.9pp | 0.4%+2.6pp | -1.9%-0.9pp | -2.1%+2.3pp | 17.9%+43.2pp |
| Current Ratio | 2.31-0.7x | 4.58+1.3x | 3.40-0.7x | 2.86-1.1x | 3.03-1.1x | 3.30-0.8x | 4.11-0.2x | 3.94-0.1x |
| Liabilities-to-Equity | 0.370.0x | 0.25-0.1x | 0.310.0x | 0.36+0.1x | 0.39-0.4x | 0.36-0.4x | 0.29-0.5x | 0.30-0.5x |
| Asset Turnover | 0.220.0x | 0.25+0.1x | 0.29+0.1x | 0.26+0.1x | 0.23+0.1x | 0.200.0x | 0.170.0x | 0.180.0x |
| FCF Margin | 8.0%-28.1pp | 21.8%+11.5pp | 0.4%+33.8pp | N/A | 36.0% | 10.3% | -33.3% | N/A |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CareDx, Inc. CDNA | FY2025 | $379.8M | -$21.4M | -5.6% | $3.9B | 51/100 |
| Adaptive Biotechnologies Corporation ADPT | FY2025 | $277.0M | -$59.5M | -21.5% | $4.6B | 70/100 |
| BillionToOne, Inc. BLLN | FY2025 | $305.1M | $7.5M | 2.4% | $4.7B | 58/100 |
| GRAIL, Inc. GRAL | FY2025 | $147.2M | -$408.4M | N/A | $4.8B | 65/100 |
| Sotera Health Company SHC | FY2025 | $1.2B | $77.9M | 6.7% | $4.6B | 55/100 |
| RadNet, Inc. RDNT | FY2025 | $2.0B | -$18.7M | -0.9% | $5.9B | 55/100 |
Where CareDx, Inc. Ranks
Frequently Asked Questions
CareDx, Inc. (CDNA) reported $379.8M in total revenue for fiscal year 2025. This represents a 13.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
CareDx, Inc. (CDNA) revenue grew by 13.8% year-over-year, from $333.8M to $379.8M in fiscal year 2025.
Yes, CareDx, Inc. (CDNA) reported a net income of $128.6M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $21.4M, with a net profit margin of -5.6%.
CareDx, Inc. (CDNA) had EBITDA of -$15.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
CareDx, Inc. (CDNA) had an operating margin of -8.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
CareDx, Inc. (CDNA) had a net profit margin of -5.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
CareDx, Inc. (CDNA) has a return on equity of -7.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
CareDx, Inc. (CDNA) generated $42.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
CareDx, Inc. (CDNA) had $413.2M in total assets as of fiscal year 2025, including both current and long-term assets.
CareDx, Inc. (CDNA) invested $71.4M in research and development during fiscal year 2025.
CareDx, Inc. (CDNA) had a current ratio of 2.86 as of fiscal year 2025, which is generally considered healthy.
CareDx, Inc. (CDNA) had a liabilities-to-equity ratio of 0.36 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
CareDx, Inc. (CDNA) had a return on assets of -5.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
CareDx, Inc. (CDNA) trades at 30.5x earnings, its market capitalization divided by $128.6M net income, trailing 12 months to September 30, 2026. The market capitalization is $3.9B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
CareDx, Inc. (CDNA) trades at 7.9x sales, its market capitalization divided by $497.4M revenue, trailing 12 months to September 30, 2026. The market capitalization is $3.9B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
CareDx, Inc. (CDNA) has an Altman Z-Score of 20.41, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
CareDx, Inc. (CDNA) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
CareDx, Inc. (CDNA) reported a net loss of $21.4M while generating $42.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
CareDx, Inc. (CDNA) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For CareDx, Inc. it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.